A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics

[1]  D. Sachs,et al.  Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity , 2021, Immunity.

[2]  N. Kodera,et al.  Direct visualization of translational GTPase factor pool formed around the archaeal ribosomal P-stalk by high-speed AFM , 2020, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Qin,et al.  Biomimetic Human Disease Model of SARS‐CoV‐2‐Induced Lung Injury and Immune Responses on Organ Chip System , 2020, Advanced science.

[4]  Tudor I. Oprea,et al.  Virtual and In Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19 , 2020, ACS pharmacology & translational science.

[5]  Donald E. Ingber,et al.  Is it Time for Reviewer 3 to Request Human Organ Chip Experiments Instead of Animal Validation Studies? , 2020, Advanced science.

[6]  B. La Scola,et al.  Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation , 2020, Travel Medicine and Infectious Disease.

[7]  Mathias W Pletz,et al.  SARS-CoV-2 causes severe alveolar inflammation and barrier dysfunction , 2020, bioRxiv.

[8]  W. Dowling,et al.  Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients , 2020, Nature Communications.

[9]  Krystal L. Matthews,et al.  Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo , 2020, Journal of Virology.

[10]  J. Mckinney,et al.  Rapid endothelialitis and vascular inflammation characterise SARS-CoV-2 infection in a human lung-on-chip model , 2020, bioRxiv.

[11]  Tokiko Watanabe,et al.  Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development , 2020, Proceedings of the National Academy of Sciences.

[12]  A. Gruber,et al.  Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters , 2020, bioRxiv.

[13]  Emily G McDonald,et al.  A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 , 2020, The New England journal of medicine.

[14]  Kazuo Takayama.  In Vitro and Animal Models for SARS-CoV-2 research , 2020, Trends in Pharmacological Sciences.

[15]  Xilong Deng,et al.  Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial , 2020, Med.

[16]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[17]  Fabian J Theis,et al.  SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes , 2020, Nature Medicine.

[18]  Kohei Oishi,et al.  Human organ chip-enabled pipeline to rapidly repurpose therapeutics during viral pandemics , 2020, bioRxiv.

[19]  Q. Bassat,et al.  Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. , 2020, JAMA network open.

[20]  Yan Liu,et al.  Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV , 2020, Nature Communications.

[21]  Tony Y. Hu,et al.  Insights from nanomedicine into chloroquine efficacy against COVID-19 , 2020, Nature Nanotechnology.

[22]  David Shum,et al.  Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs , 2020, Antimicrobial Agents and Chemotherapy.

[23]  Fumihiro Kato,et al.  Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells , 2020, Proceedings of the National Academy of Sciences.

[24]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[25]  D. Ingber,et al.  Biology-Inspired Microphysiological Systems to Advance Patient Benefit and Animal Welfare in Drug Development , 2020, ALTEX.

[26]  M. Letko,et al.  Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.

[27]  Hongzhou Lu,et al.  Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia , 2020 .

[28]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[29]  Richard Novak,et al.  Quantitative prediction of human pharmacokinetic responses to drugs via fluidically coupled vascularized organ chips , 2020, Nature Biomedical Engineering.

[30]  Carlos F. Ng,et al.  On-chip recapitulation of clinical bone-marrow toxicities and patient-specific pathophysiology , 2019, Nature Biomedical Engineering.

[31]  J. Luban.  SARS-CoV-2 , 2020 .

[32]  Joshua C. Johnson,et al.  In Vivo Activity of Amodiaquine against Ebola Virus Infection , 2019, Scientific Reports.

[33]  Myrtle Davis,et al.  Microphysiological lung models to evaluate the safety of new pharmaceutical modalities: a biopharmaceutical perspective. , 2019, Lab on a chip.

[34]  Stephen J. Huang,et al.  Neutrophils-related host factors associated with severe disease and fatality in patients with influenza infection , 2019, Nature Communications.

[35]  W. Simonson.  Influenza treatment with antiviral medications. , 2019, Geriatric Nursing.

[36]  H. Clevers,et al.  Tropism, replication competence, and innate immune responses of influenza virus: an analysis of human airway organoids and ex-vivo bronchus cultures. , 2018, The Lancet. Respiratory medicine.

[37]  K. Meng,et al.  Triterpenoids manipulate a broad range of virus-host fusion via wrapping the HR2 domain prevalent in viral envelopes , 2018, Science Advances.

[38]  K. To,et al.  Differentiated human airway organoids to assess infectivity of emerging influenza virus , 2018, Proceedings of the National Academy of Sciences.

[39]  M. Estes,et al.  Human organoid cultures: transformative new tools for human virus studies. , 2018, Current opinion in virology.

[40]  Mahadevabharath R. Somayaji,et al.  Physiologically Based Pharmacokinetic and Pharmacodynamic Analysis Enabled by Microfluidically Linked Organs-on-Chips. , 2018, Annual review of pharmacology and toxicology.

[41]  V. Papayannopoulos.  Neutrophil extracellular traps in immunity and disease , 2017, Nature Reviews Immunology.

[42]  Peng Wu,et al.  Relative incidence and individual-level severity of seasonal influenza A H3N2 compared with 2009 pandemic H1N1 , 2017, BMC Infectious Diseases.

[43]  L. Naesens,et al.  Airway proteases: an emerging drug target for influenza and other respiratory virus infections , 2017, Current Opinion in Virology.

[44]  M. Dolovich,et al.  Airway Epithelial Cell Cilia and Obstructive Lung Disease , 2016, Cells.

[45]  H. Jia.  Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease , 2016, Shock.

[46]  D. Stuart,et al.  Toremifene interacts with and destabilizes the Ebola virus glycoprotein , 2016, Nature.

[47]  Anna Huttenlocher,et al.  Neutrophil migration in infection and wound repair: going forward in reverse , 2016, Nature Reviews Immunology.

[48]  A. Azman,et al.  Effect of Artesunate-Amodiaquine on Mortality Related to Ebola Virus Disease. , 2016, The New England journal of medicine.

[49]  Thomas C. Ferrante,et al.  Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro , 2015, Nature Methods.

[50]  Lisa E. Hensley,et al.  A screen of approved drugs and molecular probes identifies therapeutics with anti–Ebola virus activity , 2015, Science Translational Medicine.

[51]  T. Kuiken,et al.  Pathogenesis of influenza-induced acute respiratory distress syndrome. , 2014, The Lancet. Infectious diseases.

[52]  M. Chan,et al.  Use of ex vivo and in vitro cultures of the human respiratory tract to study the tropism and host responses of highly pathogenic avian influenza A (H5N1) and other influenza viruses. , 2013, Virus research.

[53]  S. Mubareka,et al.  The lung microvascular endothelium as a therapeutic target in severe influenza. , 2013, Antiviral research.

[54]  Kathryn L. Schornberg,et al.  FDA-Approved Selective Estrogen Receptor Modulators Inhibit Ebola Virus Infection , 2013, Science Translational Medicine.

[55]  Daniel C Leslie,et al.  A Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice , 2012, Science Translational Medicine.

[56]  D. Ingber,et al.  Reconstituting Organ-Level Lung Functions on a Chip , 2010, Science.

[57]  V. Sinou,et al.  Pharmacokinetics and pharmacodynamics of a new ACT formulation: Artesunate/Amodiaquine (TRIMALACT®) following oral administration in African malaria patients , 2009, European Journal of Drug Metabolism and Pharmacokinetics.

[58]  J. Geddes,et al.  What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.

[59]  P. Olliaro,et al.  Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers , 2008, European Journal of Clinical Pharmacology.

[60]  Thijs Kuiken,et al.  H5N1 Virus Attachment to Lower Respiratory Tract , 2006, Science.

[61]  K. Hattermann,et al.  Susceptibility of different eukaryotic cell lines to SARS-coronavirus , 2005, Archives of Virology.

[62]  H. Atkins,et al.  VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. , 2003, Cancer cell.

[63]  Y. Guan,et al.  Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? , 2002, The Lancet.

[64]  F Y Aoki,et al.  Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. , 2000, Lancet.

[65]  Agranulocytosis associated with the use of amodiaquine for malaria prophylaxis. , 1986, MMWR. Morbidity and mortality weekly report.

[66]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.